Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds ...

Chuck Magro, CEO of seed and pesticide giant Corteva, discusses the challenges facing farmers that his company is investing millions in to fight, the potentially transformative power of gene editing ...

GEN ranks not only the top 10 publicly traded developed of editing-based therapies, but the top five privately held companies ...

Supernus Pharmaceuticals (Nasdaq: SUPN) is to buy Sage Therapeutics (Nasdaq: SAGE) for total consideration of around $795 million. Shares in Sage shot up by 35% amid the news by midday Monday, while ...

Jim Herlihy, a regional spokesman for the Alzheimer’s Association, will tell you that Kocherhans finds himself in good, if ...

In this video, Peter K. Kaiser, MD, founding director of the Digital Eye Optical Coherence Tomography Reading Center at the Cole Eye Institute, discusses treatment options for wet age-related macular ...

The Cannes Lions-winning work answered the question of how to promote Viagra in a country where pharma ads are banned and intimacy is considered a taboo subject.

In this video, Peter K. Kaiser, MD, founding director of the Digital Eye Optical Coherence Tomography Reading Center at the Cole Eye Institute, discusses the impact of wet age-related macular ...

Strategic actions by Supernus, Teva, Incyte, and BioNTech highlight growing momentum in advancing clinical-stage therapies ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential.

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...